North American In Vitro Diagnostic Market size is projected to cross USD 49 billion by 2027, according to a latest forecast report by Graphical Research.
In vitro diagnostics (IVD) involves medical devices that are used along with assays, kits, and reagents to diagnose a medical condition. Furthermore, these devices examine a patient's bodily fluids and tissue samples. There are numerous types of in vitro diagnostic devices that work with various approaches such as immunodiagnostics, tissue diagnostics, hematology, and molecular diagnostics. In vitro diagnostics are also used to diagnose cancer, infectious diseases, kidney disorders, and heart disorders among other medical conditions. IVD products are utilized in hospitals, diagnostic centers, and standalone laboratories. Moreover, the newly introduced in vitro diagnostic devices are easy to use and cost effective, thus increasing their popularity among healthcare professionals. Also, there are several over-the-counter diagnostic products available in the market, including glucose monitoring kits. These products are primarily preferred by the elderly in order to reduce the number of hospital visits. During the COVID-19 pandemic, the importance of these products has grown as people prefer convenient diagnostic tests that can be performed in home care settings. With growing number of people realizing the benefits of in vitro diagnostics products and increasing awareness about disease diagnosis.
The instrument segment accounted for more than USD 9 billion revenue in 2020 as increasing usage of instruments to diagnose chronic diseases coupled with major players focusing on development of advanced instruments. Furthermore, increasing demand for point of care in vitro diagnostics devices and rising adoption of these devices promotes the segmental as well as market expansion. For instance, in March 2021 Roche introduced Cobas 5800, a fully automated low throughput PCR system. This product is used to detect novel coronavirus.
The molecular diagnostics segment held around 22% market share in 2020 attributed to the pandemic, that has upsurged the demand for molecular diagnostics techniques to diagnose the SARS-COV-2. Moreover, there was increased demand for consumables and test kit for monitoring blood glucose levels among hospitalized patient suffering from COVID-19. This has increased the demand for point of care test based on molecular and serology techniques across the globe. In addition, owing to the increased demand for advanced technologies like RT-PCR, the molecular diagnostic segment is set to market demand.
Browse detailed statistical insights from the report, “North America In Vitro Diagnostics (IVD) Market Forecast 2027 By End-Use (Hospitals, Diagnostic Laboratories, Academic & Research Institutes), By Product Type (Reagents & Kits, Instruments), By Test Type (Clinical Chemistry, Immunoassay/ Immunochemistry, Molecular Diagnostics, Hematology, Urinalysis), By Application (Oncology, Infectious Diseases, Diabetes, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing/Pharmacogenomics), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The oncology segment dominated over USD 6.5 billion revenue in 2020 due to increasing number of cancer cases in North America. For instances, according to National Cancer Institute, In the United States in 2020, an estimated 1,806,590 new cases of cancer were diagnosed, with 606,520 people died from the disease. Similarly, in the U.S. as of January 2019, there were an estimated 16.9 million cancer survivors. By 2030, the number of cancer survivors is expected to reach 22.2 million. Furthermore, in vitro diagnostics help to determine whether a person is at risk of developing a specific type of cancer. Due to such benefits physicians prefer in vitro diagnostics products more to diagnose cancer. Additionally, the growing acceptance and availability of home care kits such as fecal occult blood test (FOBT) for diagnosing colon cancer at homecare settings, will further drive the industry growth.
The hospital segment was valued at 40% market share and accounted for around USD 11.8 billion revenue in 2020 owing to increasing number of hospitals and presence of well-established medical infrastructure in North America. Increasing preference towards hospital pharmacy owing to the high patient in-flow visiting hospitals for treatment and availability of variety of expensive medication in hospital pharmacies. In addition, growing healthcare expenditure coupled with advanced medical infrastructure are some of the factors pushing the segmental growth. Furthermore, growing usage of point of care devices including glucose meters and pregnancy kits within the hospitals increases the market demand.
The Canada in vitro diagnostic (IVD) market is poised to exhibit around 8% CAGR till 2027. Presence of well-established healthcare facilities coupled with rising demand for lab testing during the COVID-19 pandemic will prove beneficial for the market expansion. Moreover, increasing cases of cancer in this region resulting in increased demand of point-of-care diagnostics will foster the country-level growth. For instance, according to Canadian Cancer Society, in 2021, the estimated number of new cancer cases and deaths in Canada would be 229,200 and 84,600 respectively.
The North American in vitro diagnostic market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
North America Market, By Product type
- Reagents & Kits
North America Market, By Test Type
- Clinical chemistry
- Molecular diagnostics
North America Market, By Application
- Infectious diseases
- Autoimmune diseases
- Drug testing/pharmacogenomics
North America Market, By End-use
- Diagnostic laboratories
- Academic & research institutes
The above information has been provided for the following countries: